Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (NVO)
NYSE:NVO
NVO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$73.80 - $148.15
Previous CloseN/A
Volume3.65M
Average Volume (3M)7.41M
Market Cap
$335.30B
Enterprise Value$393.88B
Total Cash (Recent Filing)kr15.65B
Total Debt (Recent Filing)kr102.79B
Price to Earnings (P/E)23.4
Beta0.79
Next Earnings
May 07, 2025EPS Estimate
0.89Next Dividend Ex-Date
Mar 31, 2025Dividend Yield1.33%
Share Statistics
EPS (TTM)3.29
Shares Outstanding3,390,128,000
10 Day Avg. Volume7,467,265
30 Day Avg. Volume7,406,418
Financial Highlights & Ratios
PEG Ratio1.09
Price to Book (P/B)N/A
Price to Sales (P/S)10.10
Price to Cash Flow (P/CF)61.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$110.36Price Target Upside49.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageUBT251 has shown impressive early Phase 1b data with higher placebo-adjusted weight loss than Lilly's comparable asset, indicating promising competitive potential.
Licensing DealNovo licenses United Laboratories' triple agonist UBT251, tapping into the Chinese biotech market and showcasing the company's strategic moves in the obesity sector.
Bears Say
CagriSema PerformanceRecent REDEFINE-1/2 data for Novo's lead CagriSema asset has underwhelmed investors, leading to a potential shift in strategy with the new licensing deal.
Investor SentimentThe story for Novo shares continues to be more challenging following the results of REDEFINE-2.
---
Ownership Overview
―
Insiders
1.48% Mutual Funds
5.20% Other Institutional Investors
93.20% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NVO FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was $73.80 and its highest was $148.15 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $335.30B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is May 07, 2025 which is in 42 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Feb 05, 2025. The company reported $0.886 earnings per share for the quarter, beating the consensus estimate of $0.831 by $0.055.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.
Does Novo Nordisk pay dividends?
Novo Nordisk pays a Semiannually dividend of $0.787 which represents an annual dividend yield of 1.33%. See more information on Novo Nordisk dividends here
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.89.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of $0.886 in its last earnings report, beating expectations of $0.831. Following the earnings report the stock price went up 3.764%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in NVO
---
Novo Nordisk Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$110.36 (49.95% Upside)
$110.36 (49.95% Upside)
Blogger Sentiment
Bullish
NVO Sentiment 84%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 912.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.34%
12-Months-Change
Fundamentals
Return on Equity
82.03%
Trailing 12-Months
Asset Growth
38.79%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk is a global healthcare company based in Denmark, specializing in the development, production, and marketing of pharmaceutical products. The company operates primarily in the sectors of diabetes care, obesity, and rare blood and endocrine disorders. Novo Nordisk is renowned for its innovative insulin therapies and devices, as well as its commitment to improving the lives of people with chronic health conditions.
---
NVO Company Deck
---
NVO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong financial performance and strategic growth in key areas such as GLP-1 treatments and obesity care, supported by significant R&D achievements. However, challenges remain with increased carbon emissions, supply constraints, and issues in the rare diseases segment. Despite these challenges, the positive developments in sales, profit, and R&D outcomes suggest more highlights than lowlights.Read More>---
NVO Stock 12 Month Forecast
Average Price Target
$110.36
▲(49.95% Upside)
Technical Analysis
Best Analysts Covering NVO
1 Year
1 Year Success Rate
8/23 ratings generated profit
1 Year Average Return
-1.63%
reiterated a buy rating 29 days ago
Copying Sachin Jain's trades and holding each position for 1 Year would result in 34.78% of your transactions generating a profit, with an average return of -1.63% per trade.
---